© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
February 20, 2022
Neoadjuvant cabozantinib was safe and induced a reduction in tumor size in all patients with locally advanced nonmetastatic clear cell renal cell carcinoma enrolled in a phase 2 trial.
September 17, 2021
Patients with VHL-mutated ccRCC and VHL–wild type disease often had low positive PD-L1 expression.
February 12, 2021
The higher starting dose of lenvatinib was also associated with a prolonged time to deterioration.